After ViVE (Los Angeles): What Buyers Will Actually Do Now

Why this issue exists

Every conference has two versions. The one that happens on stage, and the one that happens when buyers get home and look at their bank statements.

ViVE 2026 in Los Angeles was the transition point where digital health moved from "experimental ambition" to operational accountability. While the floor was buzzing about Agentic AI, the subtext in the executive suites was about survival. Because once the snow clears in LA, buyers return to a far less exciting reality: their margins.

Curb moment: In Los Angeles, innovation feels inevitable. Back at the hospital, it has to survive procurement.

The Primary Signal: Hospital Margins and the "Trifurcation"

The margin math is no longer theoretical; it's an operating floor. While averages look stable, we are witnessing a "trifurcation" of the hospital sector that is reshaping purchasing power:

The Median Trap: The median operating margin for health systems sat at a modest 1.1% at the end of 2025.

The Gap: High-performers (the top 5%) are thriving with 32% margins, while the bottom 40% are struggling at negative 19%.

The Budget Chokehold: Every purchase must now justify itself as a direct margin-defense tool. Medicare continues to reimburse roughly 83 cents for every dollar spent on care, leaving systems to bridge the gap through radical efficiency or nothing at all.

Curb moment: When margins shrink, curiosity shrinks with them.

The ViVE Signal: Platform > Point Solution

The most repeated sentiment from the CHIME stage was the death of the "one app for one problem" era. Health systems are suffering from "vendor sprawl" and "fragmentation taxes."

The Tool Surcharge: Nearly 60% of CIOs are managing more than 50 different point solutions. They aren't looking for solution #51; they are looking to consolidate.

The Merck Directive: Bill Taranto, President of the Merck Global Health Innovation Fund, is now explicitly advising startups to build ecosystems rather than isolated tools.

The "Smart Thermostat" Moment: Saad Chaudhry (Providence) noted at ViVE that implementing AI without redesigned workflows is like "buying a smart thermostat only to discover your home doesn't have central air."

Curb moment: If it adds another login, enthusiasm drops quickly.

AI Must Now Prove "Operational UX"

The conversation has matured from "What can AI do?" to "What does it replace?"

Workforce Equity: A core signal from the Health Tech Nerds community highlights that AI must be co-designed with clinicians to solve the 43% burnout rate rather than just automating the care itself.

The RCM Lever: Buyers are prioritizing AI for Revenue Cycle Management (RCM) and automated coding to capture missing revenue in a tight market.

Curb moment: AI shouldn't just suggest work; it should do the work.

Policy Signals: The Regulatory Squeeze

Federal leadership at the end of February provided a snapshot of the "Great Healthcare Plan":

TrumpRx Launch: A new discount prescription drug platform that bypasses traditional insurance loops.

Fraud Crackdown: Vice President JD Vance and CMS Administrator Mehmet Oz announced a massive coordinated effort to combat fraud in Medicare and Medicaid.

Enrollment Moratorium: CMS issued a six-month nationwide moratorium on new DMEPOS suppliers to tighten the oversight belt.

Pharma's Reality: From Novelty to Evidence

Pharma marketers are rethinking engagement as $14B is spent annually to influence just 600,000 prescribing physicians.

Omnichannel is Table-Stakes: Unified platforms (CRM + Data Analytics) are now necessary to track the prescribing "journey."

Outcomes as Proof: Marketers must now integrate real-world evidence (RWE) into their materials, as HCPs demand efficacy data beyond controlled trials.

Commercial Guidance: Selling in a Margin-Defense Year

If your post-conference follow-up feels like a generic sales template, you are already "cooked."

1. Lead with Workflow Proof: Don't send a recap; send a 1-page actuarial model showing how you reduce their specific "Validation Tax."

2. Sell Replacement, Not Possibility: If your solution doesn't replace an existing cost or tool, it will be labeled a "pilot" — and pilots are where budgets go to die.

3. Governance as a Close: 72% of buyers now state that AI governance maturity is a formal procurement gate.

Curb moment: Nobody buys potential in a margin-defense year.

The Lab Note

If you attended ViVE in LA, I'd love to hear the "booth talk." Are budgets tightening as fast as the reports suggest? Are CFOs showing up to your demos earlier in the cycle?

No hype. No promotion. Just signals.